Clinical variability and molecular heterogeneity in prostate cancer.

Prostate cancer is a clinically heterogeneous disease, with some men having indolent disease that can safely be observed, while others have aggressive, lethal disease. Over the past decade, researchers have begun to unravel some of the genomic heterogeneity that contributes to these varying clinical phenotypes. Distinct molecular sub-classes of prostate cancer have been identified, and the uniqueness of these sub-classes has been leveraged to predict clinical outcomes, design novel biomarkers for prostate cancer diagnosis, and develop novel therapeutics. Recent work has also elucidated the temporal and spatial heterogeneity of prostate cancer, helping us understand disease pathogenesis, response to therapy, and progression. New genomic techniques have provided us with a window into the remarkable clinical and genomic heterogeneity of prostate cancer, and this new perspective will increasingly impact patient care.

Asian journal of andrology. 2016 Apr 15 [Epub ahead of print]

Jonathan Shoag, Christopher E Barbieri

Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medical College, New York; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, USA.